Inhibition of plasma kallikrein and activated factor XII has been central to this progress, with several new treatments now available for acute angioedema attacks, including C1-INH concentrate, icatibant acetate, ecallantide, and recombinant C1-INH. This evidence concerns the gene KLK4 and angioedema.